skip to Main Content

Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials

Newsfeed image, light gray text on dark gray background
Davendra Sohal, MD, MPH, oncologist, Cleveland Clinic, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel (Abraxane) for resectable pancreatic adenocarcinoma.

Watch here . . .

Back To Top